CSF2 and COVID-19: Additionally, clinical trials are being conducted to examine the use of monoclonal antibodies called mavrilimumab and lenzilumab against the important pro-inflammatory cytokine, granulocyte-macrophage colony-stimulating factor (GM-CSF), which has been linked to the immune-pathogenesis of COVID-19 [44].